☆ 4.7 Article

Dose-Dependent Impairment of the Immune Response to the Moderna-1273 mRNA Vaccine by Mycophenolate Mofetil in Patients with Rheumatic and Autoimmune Liver Diseases

VACCINES (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Letter Infectious Diseases

SARS-CoV-2 infection despite high levels of vaccine-induced anti-Receptor-Binding-Domain antibodies: a study on 1110 health-care professionals from a northern Italian university hospital

Davide Ferrari et al.

CLINICAL MICROBIOLOGY AND INFECTION (2022)

添加到收藏夹

Article Rheumatology

Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study

Satveer K. Mahil et al.

Summary: The study found that patients receiving methotrexate and targeted biological therapy had similar neutralizing antibody responses after the second vaccine dose, but lower T-cell responses. The longevity of vaccine-induced antibody responses in this population is currently unknown.

LANCET RHEUMATOLOGY (2022)

添加到收藏夹

Article Surgery

Intensity of mycophenolate mofetil treatment is associated with an impaired immune response to SARS-CoV-2 vaccination in kidney transplant recipients

Marta Kantauskaite et al.

Summary: Kidney transplant recipients (KTRs) have a weaker immune response to SARS-CoV-2 vaccination compared to controls, with mycophenolate mofetil (MMF) treatment being the strongest predictor for impaired response. Adjusting MMF dose may improve the immune response in KTRs.

AMERICAN JOURNAL OF TRANSPLANTATION (2022)

添加到收藏夹

Letter Rheumatology

Temporary hold of mycophenolate augments humoral response to SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal diseases: a case series

Caoilfhionn M. Connolly et al.

ANNALS OF THE RHEUMATIC DISEASES (2022)

添加到收藏夹

Article Rheumatology

Humoral and Cellular Immune Responses to SARS-CoV-2 Infection and Vaccination in Autoimmune Disease Patients With B Cell Depletion

David Simon et al.

Summary: The study found that B cell depletion completely blocks humoral response to SARS-CoV-2 vaccination, but not T cell response. Limited humoral immune responses were observed in patients with B cell depletion after SARS-CoV-2 infection.

ARTHRITIS & RHEUMATOLOGY (2022)

添加到收藏夹

Editorial Material Rheumatology

Effect of mycophenolate mofetil dose on antibody response following initial SARS-CoV-2 vaccination in patients with systemic sclerosis

Rachel Wallwork et al.

LANCET RHEUMATOLOGY (2022)

添加到收藏夹

Article Rheumatology

The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study

Satveer K. Mahil et al.

Summary: Patients receiving methotrexate may have impaired humoral immunity to a single dose of the BNT162b2 vaccine, but not those receiving targeted biologics. Cellular immune responses are preserved in all groups. Real-world pharmacovigilance studies are needed to determine the clinical effectiveness of these findings.

LANCET RHEUMATOLOGY (2021)

添加到收藏夹

Article Rheumatology

Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study

Matthias B. Moor et al.

Summary: The study investigated immune responses to SARS-CoV-2 mRNA vaccines in patients receiving CD20-targeted B-cell-depleting therapies. Results showed blunted immune responses in these patients, indicating potential challenges in vaccination strategies for this population.

LANCET RHEUMATOLOGY (2021)

添加到收藏夹

Article Virology

Weak correlation between antibody titers and neutralizing activity in sera from SARS-CoV-2 infected subjects

Elena Criscuolo et al.

Summary: This study compared two serologic tests for SARS-CoV-2, showing an increase in sensitivity over time and high specificity. However, a poor direct correlation between antibody levels and neutralizing activity was observed. These findings highlight the importance of further research on antibody kinetics and the role of neutralizing antibodies for the development of effective vaccines.

JOURNAL OF MEDICAL VIROLOGY (2021)

添加到收藏夹

Letter Medicine, General & Internal

Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination

Alicia T. Widge et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Rheumatology

SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases

David Simon et al.

Summary: Immune response against SARS-CoV-2 is delayed and reduced in patients with immune-mediated inflammatory diseases, regardless of treatment.

ANNALS OF THE RHEUMATIC DISEASES (2021)

添加到收藏夹

Letter Rheumatology

Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS-CoV-2 vaccination in patients with rheumatic diseases

Robert Spiera et al.

ANNALS OF THE RHEUMATIC DISEASES (2021)

添加到收藏夹

Article Rheumatology

Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort

Ulf M. Geisen et al.

Summary: In this study, the efficacy and safety of anti-SARS-CoV-2 mRNA vaccines in immunosuppressed patients were compared with healthy controls. The results showed that all study participants developed antibodies, with lower IgG titres in patients compared to controls. Side effects were minimal and no disease flares were observed, demonstrating the efficiency and safety of mRNA vaccines in this cohort despite its small size.

ANNALS OF THE RHEUMATIC DISEASES (2021)

添加到收藏夹

Article Cell Biology

Highly Specific Memory B Cells Generation after the 2nd Dose of BNT162b2 Vaccine Compensate for the Decline of Serum Antibodies and Absence of Mucosal IgA

Eva Piano Mortari et al.

Summary: Specific memory B cells and antibodies significantly increase after the second dose of BNT162b2 vaccine; although the vaccine does not induce mucosal IgA, memory B cells can migrate in response to inflammation and secrete IgA at mucosal sites; the first vaccine dose may not provide sufficient immune robustness due to insufficient memory B cells and low antibody levels.

CELLS (2021)

添加到收藏夹

Article Rheumatology

Efficacy of anti-SARS-CoV-2 mRNA vaccine in systemic autoimmune disorders: induction of high avidity and neutralising anti-RBD antibodies

Chiara Tani et al.

Summary: Double-dose vaccination in patients with SARDs induced anti-RBD IgG and IgA antibodies in amounts not significantly different from controls, characterized by high avidity and neutralizing activity.

RMD OPEN (2021)

添加到收藏夹

Review Rheumatology

COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses

Filippo Fagni et al.

Summary: Patients with immune-mediated inflammatory diseases do not have an increased risk of SARS-CoV-2 infection or severe COVID-19, and certain medications like cytokine inhibitors may even lower the risk of severe illness. However, glucocorticoids might worsen COVID-19 outcomes, and the immune response to vaccination in these patients could be somewhat reduced.

LANCET RHEUMATOLOGY (2021)

添加到收藏夹

Article Rheumatology

American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 1

Jeffrey R. Curtis et al.

Summary: This study aims to provide guidance to rheumatology providers on the use of COVID-19 vaccines in patients with rheumatic and musculoskeletal diseases. Despite limited direct evidence, consensus statements from the task force offer guidance and recommendations for vaccination strategies for RMD patients.

ARTHRITIS & RHEUMATOLOGY (2021)

添加到收藏夹

Article Rheumatology

Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study

Victoria Furer et al.

Summary: Vaccination with mRNA BNT162b2 vaccine showed reduced immunogenicity in patients with AIIRD compared to the general population, with risk factors including older age and treatment with glucocorticoids, rituximab, mycophenolate mofetil (MMF), and abatacept. However, most patients maintained stable disease activity post-vaccination.

ANNALS OF THE RHEUMATIC DISEASES (2021)

添加到收藏夹

Article Rheumatology

Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2

Yolanda Braun-Moscovici et al.

Summary: The vast majority of patients with inflammatory rheumatic diseases developed a significant humoral response following the administration of the second dose of the Pfizer mRNA vaccine against SARS-CoV-2 virus. Only minor side effects were reported and no apparent impact on IRD activity was noted.

ANNALS OF THE RHEUMATIC DISEASES (2021)

添加到收藏夹

Letter Rheumatology

High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases

Jake A. Ruddy et al.

ANNALS OF THE RHEUMATIC DISEASES (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum

Chang Liu et al.

Summary: Recent study examined the neutralizing ability of monoclonal antibodies, convalescent and vaccine sera against the Indian variants B.1.617.1 and B.1.617.2, showing that the neutralization of these variants is reduced compared to the ancestral strains, without widespread antibody escape as seen in other variants like B.1.351.

CELL (2021)

添加到收藏夹

Editorial Material Immunology

5 reasons to encourage anti-SARS-CoV-2 vaccination in patients with rheumatic diseases

Francesca Motta et al.

EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial

Ana C. Medeiros-Ribeiro et al.

Summary: In a large prospective phase 4 trial, vaccination with CoronaVac, an inactivated SARS-CoV-2 vaccine, elicited significantly lower virus-specific IgG antibodies and neutralizing antibodies in patients with autoimmune rheumatic diseases than in age- and sex-matched healthy control trial participants.

NATURE MEDICINE (2021)

添加到收藏夹

Article Rheumatology

American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 3

Jeffrey R. Curtis et al.

Summary: A task force composed of rheumatologists, infectious disease specialists, and public health physicians developed 74 draft guidance statements regarding the use of COVID-19 vaccines in patients with rheumatic and musculoskeletal diseases, aiming to provide direction to rheumatology providers and facilitate vaccination strategies for RMD patients based on limited clinical data.

ARTHRITIS & RHEUMATOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

BNT162b2 mRNA COVID-19 vaccination in immunocompromised patients: A prospective cohort study

Galia Rahav et al.

Summary: The antibody response to the Pfizer-BioNTech vaccine varied significantly among different immunocompromised patients, suggesting the need for individual recommendations based on specific immunosuppression states.

ECLINICALMEDICINE (2021)

添加到收藏夹

Article Immunology

Humoral response to a 13-valent pneumococcal conjugate vaccine in kidney transplant recipients

Simon Oesterreich et al.

VACCINE (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity

Carolyn Rydyznski Moderbacher et al.

CELL (2020)

添加到收藏夹

Article Medicine, General & Internal

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Edward E. Walsh et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Rheumatology

Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial

Jin Kyun Park et al.

ANNALS OF THE RHEUMATIC DISEASES (2017)

添加到收藏夹

Review Rheumatology

Vaccination of patients with autoimmune inflammatory rheumatic diseases

Johanna Westra et al.

NATURE REVIEWS RHEUMATOLOGY (2015)

添加到收藏夹

Article Urology & Nephrology

Response of Transplant Recipients to Influenza Vaccination Based on Type of Immunosuppression: A Meta-analysis

Reza Karbasi-Afshar et al.

SAUDI JOURNAL OF KIDNEY DISEASES AND TRANSPLANTATION (2015)

添加到收藏夹

Review Rheumatology

Effects of biological and non-biological immunomodulatory therapies on the immunogenicity of vaccines in patients with rheumatic diseases

Zsuzsanna H. McMahan et al.

ARTHRITIS RESEARCH & THERAPY (2014)

添加到收藏夹

Article Immunology

Suppression of Vaccine Immunity by Inflammatory Monocytes

Leah A. Mitchell et al.

JOURNAL OF IMMUNOLOGY (2012)

添加到收藏夹

Article Immunology

The combination of GM-CSF and IL-2 as local adjuvant shows synergy in enhancing peptide vaccines and provides long term tumor protection

Antoun Toubaji et al.

VACCINE (2007)

添加到收藏夹

Article Cell Biology

Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don't know

YF Shi et al.

CELL RESEARCH (2006)

添加到收藏夹

Review Medicine, General & Internal

Antiinflammatory action of glucocorticoids - New mechanisms for old drugs

T Rhen et al.

NEW ENGLAND JOURNAL OF MEDICINE (2005)

添加到收藏夹

Article Immunology

Restriction of de novo nucleotide biosynthesis interferes with clonal expansion and differentiation into effector and memory CD8 T cells

L Quéméneur et al.

JOURNAL OF IMMUNOLOGY (2004)

添加到收藏夹

Article Immunology

Mycophenolate mofetil inhibits differentiation, maturation and allostimulatory function of human monocyte-derived dendritic cells

M Colic et al.

CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2003)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.